Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

MBL2and Hepatitis C Virus Infection among Injection Drug Users

  • Elizabeth E Brown1,
  • Mingdong Zhang1,
  • Rebecca Zarin-Pass1,
  • Toralf Bernig2,
  • Fan-Chen Tseng1,
  • Nianqing Xiao3,
  • Meredith Yeager3,
  • Brian R Edlin4, 5,
  • Stephen J Chanock1, 2 and
  • Thomas R O'Brien1Email author
BMC Infectious Diseases20088:57

DOI: 10.1186/1471-2334-8-57

Received: 07 August 2007

Accepted: 01 May 2008

Published: 01 May 2008

Abstract

Background

Genetic variations in MBL2 that reduce circulating levels and alter functional properties of the mannose binding lectin (MBL) have been associated with many autoimmune and infectious diseases. We examined whether MBL2 variants influence the outcome of hepatitis C virus (HCV) infection.

Methods

Participants were enrolled in the Urban Health Study of San Francisco Bay area injection drug users (IDU) during 1998 through 2000. Study subjects who had a positive test for HCV antibody were eligible for the current study. Participants who were positive for HCV RNA were frequency matched to those who were negative for HCV RNA on the basis of ethnicity and duration of IDU. Genotyping was performed for 15 single nucleotide polymorphisms in MBL2. Statistical analyses of European American and African American participants were conducted separately.

Results

The analysis included 198 study subjects who were positive for HCV antibody, but negative for HCV RNA, and 654 IDUs who were positive for both antibody and virus. There was no significant association between any of the genetic variants that cause MBL deficiency and the presence of HCV RNA. Unexpectedly, the MBL2 -289X promoter genotype, which causes MBL deficiency, was over-represented among European Americans who were HCV RNA negative (OR = 1.65, 95% CI 1.05–2.58), although not among the African Americans.

Conclusion

This study found no association between genetic variants that cause MBL deficiency and the presence of HCV RNA. The observation that MBL2 -289X was associated with the absence of HCV RNA in European Americans requires validation.

Background

Mannose binding lectin (MBL) is an acute phase reactant that is secreted from the liver and is critical in host defenses against a spectrum of bacterial, fungal, viral, and parasitic pathogens. MBL directly mediates opsonophagocytosis and acvation of the C-type lectin complement pathway by binding microbial mannose and N-acetylglucosamine surface residues. MBL deficiency has been associated with a range of auto-immune and infectious diseases, including HIV-1 and hepatitis B viral infections [14].

Low circulating levels of MBL have been associated with common genetic variants in the MBL2 gene, which is the only functional human gene for MBL. MBL2 is located on the long arm of chromosome 10 (10q11.2-11) and consists of four exons [5]. Exon 1 includes three nonsynonymous single nucleotide polymorphisms (SNPs), known as D, B and C alleles, that alter the function as well as circulating levels of MBL [6, 7]. These SNPs, in combination with two proximal promoter variants (-618H/L and -289Y/X) [8, 9] and a variant in the 5' untranslated region (UTR) of MBL2 (-65Q/P) [6], form seven well-characterized 'secretor' haplotypes that alter functional activity, namely, opsonophagocytosis, complement-activation and circulating levels of MBL [10].

In the United States, chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma. The medical literature on MBL and HCV infection is limited. Most previous studies focus on the relationship between MBL2 variants and either response to antiviral treatment or the risk of developing fibrosis/cirrhosis [11]. In the present study, we evaluated whether common variations in MBL2 influence the spontaneous resolution of HCV infection in a population of injection drug users (IDU).

Methods

Study population

The present analysis is part of a comprehensive evaluation of the relationship between human genetics and HCV infection among IDUs enrolled in the Urban Health Study (UHS). As previously described [12], participants enrolled in UHS were recruited from street settings in six inner-city San Francisco Bay area neighborhoods. All persons 18 years of age or older were eligible for enrollment if they had injected drugs within the past 30 days or previously participated in the Urban Health Study. New participants were screened for visible signs of recent or chronic injection (i.e., recent venipuncture sites or scars). After the participant provided written informed consent, a blood sample and responses to a questionnaire were collected. Study procedures were approved by Committee on Human Subjects Research at University of California, San Francisco and the Institutional Review Board of the National Cancer Institute.

Participants enrolled in the UHS from 1998 through 2000 who had a positive test for HCV antibody were eligible for the current study, which is a case-control study based on cross-sectional data. These participants were tested for HCV RNA. Those positive for HCV RNA were frequency matched (maximum 4:1 ratio) to those who were negative for HCV RNA on the basis of self-reported ethnic background and duration of IDU (± 5 years). Because IDUs had very limited access to anti-HCV treatment at the time of subject recruitment [13, 14], it is highly likely that the HCV RNA negative subjects in this study had recovered spontaneously. Participants who were positive for HBV surface antigen (HBsAg) were later excluded from the analyses because of the complex relationship between HCV infection and HBV infection in this population [24]. The subjects of this analysis consisted of 198 HCV RNA negative participants (109 European Americans and 89 African Americans) and 654 HCV RNA positive participants (344 European Americans and 310 African Americans).

Laboratory methods

Viral assays

We detected HCV antibodies using the HCV EIA version 3 (Ortho Diagnostics, Raritan, NJ), HCV RNA by a branched-chain DNA assay (HCV bDNA version 3.0, Bayer, Tarrytown, NY; analytic sensitivity, 2.5 × 103 copies/ml) and HBsAg with the Genetic Systems HBsAg EIA (Bio-Rad, Redmond, WA). We tested for antibodies to HIV-1 infection in plasma using the Genetic Systems rLAV EIA assay (Bio-Rad, Redmond, WA). Reactive samples were confirmed by HIV-1 Western Blot (Cambridge Biotech, Worcester, MA).

Genotyping

Based on recent resequencing of MBL2, we selected fifteen SNPs from exonic, intronic and promoter regions of MBL2 to include loci that were previously associated with circulating MBL levels and to capture haplotype diversity in both the 5' and 3' blocks (Table 1) [15, 16]. Information on all assays is publicly available (including primers, probes and conditions) on the SNP500 Cancer website [17, 18]. Details of the nomenclature used to describe these sequence variations are also available [19, 20]. We extracted genomic DNA from cryopreserved lymphocytes using a modified salt precipitation-extraction method (Gentra Systems, Minneapolis, MN) or from granulocytes using a silica membrane binding method (Qiagen Inc., Valencia, CA). Genotyping was performed using optimized TaqMan™ assays and analyzed on the ABI 7900HT platform (ABI, Foster City, CA). We identified duplicate subjects with the AmpFLSTR Profiler Plus® PCR amplification kit (PE Applied Biosystems, Foster City, CA) to type nine tetranucleotide short tandem repeat loci and the Amelogenin locus. A blinded duplicate analysis of 5% of study samples demonstrated greater than 99% concordance.
Table 1

Common variants of MBL2 genotyped in the Urban Health Study

Variant

dbSNP Identifier

Secretor*

Amino Acid Change

Function

T-1964C

rs1031101

   

G-618C

rs11003125

H/L (aka -550)

 

H = high, L = low

G-289C

rs7096206

Y/X (aka -221)

 

Y = high, X = low

T-65C

rs7095891

Q/P (aka +4)

  

Ex1 C-34T

rs5030737

A/D (Codon 52)

R52C

D = low

Ex1 G-27A

rs1800450

A/B (Codon 54)

G54D

B = low

Ex1 G-18A

rs1800451

A/C (Codon 57)

G57E

C = low

IVS2 G-630A

rs4935046

   

IVS2 T-250C

rs1838066

   

IVS3 G-28C

rs930508

   

Ex4 C+5G

rs930507

   

Ex4 T-1483C

rs10082466

   

Ex4 G-1067A

rs10824792

   

Ex4 G-901A

rs2120132

   

Ex4 G-710A

rs2099902

   

NOTE: Six common variants form secretor haplotypes including -618, -289, -65, Ex1 -34, Ex1 -27, Ex1 – 18. Nomenclature for description of sequence variations is described in http://snp500cancer.nci.nih.gov/terms_snp_region.cfm

Statistical analysis

All analyses were conducted separately among European American and African American participants. We first examined departure from Hardy-Weinberg proportions for each locus among the participants that were positive for HCV RNA and then evaluated differences in genotype frequencies by HCV RNA status. We estimated the relative risk of being HCV RNA negative using the prevalence odds ratio (OR) and corresponding 95% confidence interval (CI) calculated with logistic regression adjusted for sex, duration of IDU and HIV-serostatus. Consistent with some previous studies of HCV outcome, we examined odds ratios for being HCV negative because it is the rarer outcome. We did not include age in the regression models because in UHS subjects this variable is highly correlated with duration of IDU. The Pearson χ2 test was used to calculate p-values; p 0.05 (two-tailed) was considered statistically significant.

The seven classical secretor haplotypes (HYPA, LYPA, LYQA, LXPA, HYPD, LYPB and LYQC; Table 1) were analyzed based on prior studies that demonstrated associations with circulating levels of MBL. Overall heterogeneity (global score test) and individual secretor haplotype frequencies, adjusted for covariates (sex, duration of IDU and HIV-1 infection), were estimated by the expectation-maximization progressive insertion algorithm (HaploStats version 1.1.0), as previously described [21]. This method is based on empirical distributions of a minimum of 10,000 and maximum of 50,000 permutations. We also examined diplotypes formed by the Y/X promoter variant and the three common structural variants from exon 1 [10, 16]. The wild-type structural allele is designated as "A" and the nonsynonymous SNPs (D, B and C) are designated as "O".

Results

Characteristics of the study population are described in Table 2. Of the 453 European American participants, those who were HCV RNA negative did not notably differ from those who were HCV RNA positive with regard to age (median: 43 years in each group) or duration of IDU (median: cleared 23 years; chronic, 24 years). Male gender, however, was more common among HCV RNA positive participants (71.8%) compared to those who were HCV RNA negative (62.4%; p = 0.06). In addition, HIV-1 infection was more common among European American participants who were HCV RNA positive (11.9%) compared to those who were HCV RNA negative (4.6%; p = 0.03).
Table 2

General demographic characteristics of the Urban Health Study population genotyped for common variants in MBL2

 

European Americans

African Americans

 

HCV RNA Negative (n = 109)

HCV RNA Positive (n = 344)

P

HCV RNA Negative (n = 89)

HCV RNA Positive (n = 310)

P

Gender, male (%)

68 (62.4)

247 (71.8)

0.06

54 (68.7)

192 (61.2)

0.83

Age at blood draw, median years (range)

43 (25–63)

43 (23–65)

0.46

47 (31–64)

47 (28–82)

0.16

Duration of IDU, median years (range)

23 (5–41)

24 (10–49)

0.83

26 (8–44)

27 (11–51)

0.13

HIV-1 serostatus

      

   Seropositive

5 (4.6)

41 (11.9)

 

8 (9.0)

36 (11.6)

 

   Seronegative

104 (95.4)

303 (88.1)

0.03

81 (91.0)

274 (88.4)

0.49

Among the 399 African Americans included in this investigation, participants who were HCV RNA negative were similar to those who were HCV RNA positive with regard to age (median: 47 years in each group), duration of IDU (median: cleared 26 years; chronic, 27 years), gender (males: chronic, 61.9%; cleared, 60.7%) and HIV-1 infection (chronic HCV infection, 11.6%; cleared, 9.0%).

HCV RNA and MBL2 genotypes

In separate evaluations of the European American and African American participants who were positive for HCV RNA, genotypic distributions for all fifteen variants were consistent with Hardy-Weinberg proportions (P ≥ 0.05; Table 3). Among European American participants, the -289C-containing variant (-289X) of the proximal promoter, which causes MBL deficiency, was over-represented among those who were HCV RNA negative compared to participants who were positive for HCV RNA (OR = 1.65, 95% CI 1.05–2.58). There were no notable associations with the other promoter variants that have been previously shown to alter MBL levels [G618C (H/L) or T65C (P/Q)] or with either structural locus commonly found among European Americans (D or B). Associations with other MBL2 variants did not achieve statistical significance.
Table 3

Common variants in MBL2 and odds ratio for being HCV RNA negative among injection drug users

  

European Americans

African Americans

Locus

Genotype

HCV RNA Negative

%

HCV RNA Positive

%

OR (95% CI)

HCV RNA Negative

%

HCV RNA Positive

%

OR (95% CI)

T-1964C

           
 

TT

83

77.6

256

76.0

1.00

82

93.2

288

94.1

1.00

 

TC

23

21.5

73

21.7

0.94 (0.55–1.60)

6

6.8

17

5.6

1.27 (0.48–3.36)

 

CC

1

0.9

8

2.4

0.44 (0.05–3.51)

0

0.0

1

0.3

NA

 

TC + CC

24

22.4

81

24.0

0.91 (0.54–1.53)

6

6.8

18

5.9

1.20 (0.46–3.14)

G-618C (H/L)

           
 

CC

44

41.9

124

36.4

1.00

69

80.2

233

76.9

1.00

 

CG

47

44.8

164

48.1

0.80 (0.50–1.29)

15

17.4

67

22.1

0.76 (0.41–1.42)

 

GG

14

13.3

53

15.5

0.72 (0.36–1.43)

2

2.2

3

1.0

2.63 (0.42–16.43)

 

CG + GG

61

58.1

217

63.6

0.80 (0.51–1.26)

17

19.8

70

23.1

0.83 (0.46–1.50)

G-289C (Y/X)

           
 

GG

59

55.1

218

66.3

1.00

63

71.6

218

70.6

1.00

 

GC

42

39.3

103

31.3

1.56 (0.98–2.49)

23

26.1

87

28.2

0.92 (0.53–1.58)

 

CC

6

5.6

8

2.4

2.72 (0.90–8.23)

2

2.3

4

1.3

2.01 (0.35–11.42)

 

GC + CC

48

44.9

111

33.7

1.65 (1.05–2.58)

25

28.4

91

29.4

0.97 (0.57–1.63)

T-65C (P/Q)

           
 

CC

64

59.8

197

57.4

1.00

21

23.9

64

20.8

1.00

 

CT

38

35.5

127

37.0

0.93 (0.59–1.48)

43

48.9

160

51.9

0.81 (0.44–1.48)

 

TT

5

5.0

19

5.5

0.75 (0.27–2.09)

24

27.3

84

27.3

0.85 (0.43–1.67)

 

CT + TT

43

4.7

146

42.6

0.90 (0.58–1.40)

67

76.1

244

79.2

0.83 (0.47–1.47)

Ex1 C-34T (D)

           
 

CC

95

87.2

300

87.5

1.00

87

97.8

303

98.1

1.00

 

TC

13

11.9

42

12.2

1.06 (0.54–2.10)

2

2.3

6

1.9

1.11 (0.22–5.62)

 

TT

1

0.9

1

0.3

2.71 (0.16–45.25)

0

0.0

0

0.0

NA

 

TC + TT

14

12.8

43

12.5

1.00 (0.52–1.91)

2

2.3

6

1.9

1.11 (0.22–5.62)

Ex1 G-27A (B)

           
 

GG

85

78.0

256

75.5

1.00

83

93.3

285

93.4

1.00

 

GA

23

21.1

75

22.1

0.90 (0.53–1.53)

6

6.7

19

6.2

1.10 (0.42–2.86)

 

AA

1

0.9

8

2.4

0.42 (0.05–3.46)

0

0.0

1

0.3

NA

 

GA + AA

24

22.0

83

24.5

0.87 (0.52–1.46)

6

6.7

20

6.6

1.04 (0.40–2.70)

Ex1 G-18A (C)

           
 

GG

95

92.2

312

96.0

1.00

49

56.3

168

55.6

1.00

 

GA

8

7.8

13

4.0

2.26 (0.89–5.73)

29

33.3

116

38.4

0.86 (0.51–1.45)

 

AA

0

0.0

0

0.0

NA

9

10.3

18

6.0

1.68 (0.71–3.99)

 

GA + AA

8

7.8

13

4.0

2.26 (0.89–5.73)

38

43.7

134

44.4

0.97 (0.60–1.57)

IVS2 G-630A

           
 

GG

22

20.8

59

17.9

1.00

49

57.6

168

54.4

1.00

 

GA

55

51.9

161

48.8

0.89 (0.50–1.59)

31

36.5

127

41.1

0.84 (0.51–1.39)

 

AA

29

27.4

110

33.3

0.68 (0.36–1.30)

5

5.9

14

4.5

1.22 (0.41–3.60)

 

GA + AA

84

79.3

271

82.1

0.82 (0.47–1.43)

36

42.4

141

45.6

0.87 (0.54–1.42)

IVS2 T-250C

           
 

TT

42

40.4

119

35.6

1.00

72

80.9

236

76.9

1.00

 

TC

48

46.2

161

48.2

0.84 (0.52–1.36)

15

16.9

68

22.2

0.73 (0.39–1.36)

 

CC

14

13.5

54

16.2

0.72 (0.36–1.43)

2

2.3

3

1.0

2.52 (0.40–15.75)

 

TC + CC

62

59.6

215

64.4

0.83 (0.53–1.31)

17

19.1

71

23.1

0.79 (0.44–1.43)

IVS3 G-28C

           
 

GG

72

66.7

239

70.7

1.00

36

41.9

135

43.8

1.00

 

GC

34

31.5

93

27.5

1.28 (0.79–2.07)

39

45.3

144

46.8

1.02 (0.61–1.70)

 

CC

2

1.9

6

1.8

0.98 (0.19–5.00)

11

12.8

29

9.4

1.42 (0.65–3.14)

 

GC +CC

36

33.3

99

29.3

1.25 (0.78–1.99)

50

58.1

173

56.2

1.08 (0.66–1.76)

Ex4 C+5G

           
 

GG

70

66.7

244

71.6

1.00

41

46.1

143

46.6

1.00

 

GC

33

31.4

92

27.0

1.31 (0.81–2.14)

39

43.8

138

45.0

0.98 (0.60–1.62)

 

CC

2

1.9

5

1.5

1.17 (0.22–6.27)

9

10.1

26

8.5

1.22 (0.53–2.82)

 

GC + CC

35

33.3

97

28.4

1.32 (0.82–2.11)

48

53.9

164

53.4

1.02 (0.63–1.64)

Ex4 T-1483C

           
 

TT

65

60.2

193

58.5

1.00

25

28.7

88

29.6

1.00

 

TC

36

33.3

117

35.5

0.91 (0.57–1.47)

32

36.8

155

52.2

0.72 (0.40–1.30)

 

CC

7

6.5

20

6.1

1.13 (0.45–2.83)

30

34.5

54

18.2

2.02 (1.07–3.81)

 

TC + CC

43

39.8

137

41.5

0.94 (0.60–1.47)

62

71.3

209

70.4

1.05 (0.62–1.79)

Ex4 G-1067A

           
 

GG

18

17.5

46

13.8

1.00

62

72.9

199

65.9

1.00

 

GA

48

46.6

156

46.8

0.72 (0.38–1.37)

19

22.4

92

30.5

0.67 (0.38–1.20)

 

AA

37

35.9

131

39.3

0.65 (0.33–1.26)

4

4.7

11

3.6

1.31 (0.40–4.32)

 

GA +AA

85

82.5

287

86.2

0.70 (0.38–1.28)

23

27.1

103

34.1

0.73 (0.43–1.25)

Ex4 G-901A

           
 

AA

61

58.1

187

57.0

1.00

26

29.2

90

29.8

1.00

 

GA

37

35.2

118

36.0

0.97 (0.60–1.55)

35

39.3

160

53.0

0.75 (0.42–1.33)

 

GG

7

6.7

23

7.0

1.02 (0.41–2.52)

28

31.5

52

17.2

1.87 (0.99–3.53)

 

GA + GG

44

41.9

141

43.0

0.69 (0.61–1.51)

63

70.8

212

70.2

1.03 (0.61–1.73)

Ex4 G-710A

           
 

AA

65

60.7

196

58.3

1.00

18

20.2

65

21.3

1.00

 

GA

34

31.8

120

35.7

0.86 (0.54–1.39)

34

38.2

150

49.2

0.82 (0.43–1.56)

 

GG

8

7.5

20

6.0

1.31 (0.55–3.17)

37

41.6

90

29.5

1.50 (0.78–2.88)

 

GA + GG

42

39.3

140

41.7

0.92 (0.59–1.44)

71

79.8

240

78.7

1.07 (0.60–1.93)

NOTE: The most frequent homozygotes among controls served as the referent. Genotypic odds ratios were adjusted for sex, duration of injection drug use, and HIV-serostatus; OR (odds ratio); 95% CI (confidence interval); and NA, not applicable.

In contrast to our observation among European American participants, the -289C (low promoter) genotype was unrelated to HCV RNA status among African American participants (OR, 0.97; P = 0.94). Homozygosity for the C allele of the T-1483C exon 4 polymorphism, which is a synonymous variant without established functional effects, was associated with a two-fold increased likelihood of being HCV negative in the African Americans, but there was no overall association for 1483C carriers (OR, 1.05; 95% CI, 0.62–1.79). HCV clearance among African American participants was not significantly associated with other promoter, structural or intronic variants of MBL2.

HCV RNA and haplotypes of MBL2

Among European Americans, the LXPA haplotype (the only secretor haplotype containing -289C [X]) was associated with an increased likelihood of being negative for HCV RNA when compared to the HYPA haplotype (Table 4; OR = 1.73, 95% CI 1.10–2.74; p = 0.01). LXPA is associated with lower MBL levels compared to HYPA. In an additive model, each copy of LXPA was associated with a nearly 2-fold increase in risk (P-trend = 0.01). Among African American participants, there were no significant associations of secretor haplotypes and HCV RNA.
Table 4

Odds ratio for risk of being HCV RNA negative among European American and African American injection drug users, by MBL2 secretor haplotype profile.

       

Haplotype frequency estimates

 

Secretor Haplotype

Total

HCV RNA Negative

HCV RNA Positive

P

OR (95% CI)

European Americans

 

-618

-289

-65

Ex1 -34

Ex1 -27

Ex1 -18

     

HYPA

G

G

C

C

G

G

32.3%

29.2%

33.2%

0.24

referent

LYQA

C

G

T

C

G

G

21.2%

18.5%

22.1%

0.23

0.93 (0.58–1.51)

LXPA

C

C

C

C

G

G

19.5%

25.2%

17.7%

0.01

1.73 (1.10–2.74)

LYPB

C

G

C

C

A

G

12.9%

11.5%

13.3%

0.49

0.93 (0.53–1.64)

HYPD

G

G

C

T

G

G

6.5%

6.9%

6.4%

0.66

1.19 (0.59–2.39)

LYPA

C

G

C

C

G

G

5.1%

5.0%

5.1%

0.94

0.92(0.40–2.13)

LYQC

C

G

T

C

G

A

2.5%

3.9%

2.0%

0.08

3.27 (1.18–9.05)

Global score statistic

0.14

 

African Americans

LYQA

C

G

T

C

G

G

27.3%

24.8%

28.0%

0.38

referent

LYQC

C

G

T

C

G

A

25.7%

27.0%

25.3%

0.69

1.24 (0.76–2.01)

LYPA

C

G

C

C

G

G

16.5%

18.4%

15.9%

0.49

1.24(0.70–2.21)

LXPA

C

C

C

C

G

G

15.4%

15.6%

15.4%

0.89

1.23 (0.69–2.18)

HYPA

G

G

C

C

G

G

10.7%

9.8%

10.9%

0.74

1.10 (0.57–2.12)

LYPB

C

G

C

C

A

G

3.4%

3.4%

3.4%

0.91

1.15 (0.44–3.01)

HYPD

G

G

C

T

G

G

1.0%

1.1%

1.0%

0.92

1.21 (0.23–6.29)

Global score statistic

0.98

 

Relative haplotype frequencies adjusted for sex, duration of injection drug use and HIV-1 serostatus.

Haplotypes appear in order of descending haplotype frequencies among the comparison group stratified by race.

P-value for LYPC among European Americans is not statistically signficant due to permutations based on small haplotype frequencies.

The global score test evaluates differences between cases and controls in the overall haplotype distribution.

We next examined the relationship between the MBL2 Y/X, A/0 diplotypes and HCV RNA (Table 5), comparing participants who carried YA/YA, which has been associated with the highest MBL levels, to participants with other diplotypes in descending order of previously associated serum MBL levels. Among European American participants, those with XA/YO were more likely to be HCV RNA negative (OR, 2.31; 95% CI, 1.07–5.02). Collapsing the diplotypes into four categories based on a previous report of MBL levels [15], participants in the lowest category (XA/YO and YO/YO) were more likely to be HCV RNA negative than those in the highest category (YA/YA diplotype; OR, 2.00; 95% CI, 1.05–3.82). Participants in intermediate categories were no more likely to be HCV RNA negative than those with the YA/YA diplotype. There were no notable associations of any MBL Y/X, A/0 diplotype and HCV RNA among African American participants (Table 5).
Table 5

MBL2 diplotypes and odds ratio for risk of being HCV RNA negative among injection drug users

 

European Americans

African Americans

Diplotype

HCV RNA Negative

HCV RNA Positive

OR (95% CI)

OR (95% CI)*

HCV RNA Negative

HCV RNA Positive

OR (95% CI)

OR (95% CI)*

YA/YA

32.1%

37.8%

1.00

1.00

30.3%

31.3%

1.00

1.00

XA/YA

25.7%

22.7%

1.36 (0.77–2.43)

1.36 (0.77–2.43)

18.0%

18.1%

1.01 (0.50–2.05)

1.01 (0.50–2.05)

YA/YO

16.5%

24.1%

0.81 (0.43–1.55)

0.99 (0.77–1.79)

29.2%

31.0%

0.96 (0.52–1.78)

1.00 (0.55–1.83)

XA/XA

5.5%

2.3%

2.74 (0.88–8.52)

2.3%

1.3%

2.08 (0.35–12.21)

  

XA/YO

12.8%

7.3%

2.31 (1.07–5.02)

2.00

7.9%

10.0%

0.82 (0.33–2.08)

1.13

YO/YO

7.3%

5.8%

1.61 (0.65–4.03)

(1.05–3.82)

12.4%

8.4%

1.49 (0.65–3.41)

(0.57–2.24)

*OR for grouped diplotypes. Diplotypes were ordered and grouped on the basis of previously reported serum MBL levels among Caucasians [13]. Mean serum MBL [mg/l] in that report were: YA/YA, 4.78; XA/YA, 2.83; YA/YO, 1.58; XA/XA, 1.39; XA/YO, 0.19; YO/YO, 0.05.

Discussion

In this study, MBL2 genotypes or haplotypes associated with MBL deficiency were not, in general, associated with the likelihood of being negative for HCV RNA. Among European Americans, the -289C (X) promoter variant, which is associated with moderately lower MBL levels, was actually more common in participants who were negative for HCV RNA than those who were positive. Among African Americans, there was no compelling evidence of HCV RNA status with any of the MBL2 genotypes or haplotypes evaluated. To our knowledge there are no previous studies of common variation in MBL2 and spontaneous clearance of HCV infection to corroborate these results [11], but the size of the study, our multiethnic population and gene coverage suggest that clearance of HCV infection is not impaired by MBL insufficiency.

The association of HCV RNA negative status with MBL2 -289C (X) [and LXPA, the haplotype associated with -289C] among European Americans may be due to chance. This 'protective effect' is contrary to most previous observations where MBL deficiency predisposed to a worsened course of infection. In addition, MBL2 structural variants were not significantly associated with HCV RNA negative status among either European Americans or African American participants. Conversely, it should be noted that the preservation of heterozygosity for MBL2 loci and the corresponding range of circulating MBL levels suggests that low to moderate levels of MBL could be advantageous in some circumstances [16]. In that regard, an association between genotypes that produce low MBL levels and more favorable outcome among patients with tuberculosis has been reported [22]. The association of HCV RNA negative status with MBL2 -289C (X) found among European Americans in the present study requires replication.

We defined HCV outcome on the basis of results from a single HCV EIA and a single HCV bDNA assay. False positive HCV EIA results are unlikely to have affected our findings in a meaningful way because the high prevalence of HCV antibodies found among IDUs combined with the high specificity of the assay we used [23] yield a positive predictive value exceeding 99%. Because this is a case-control study based on cross-sectional data, we could not use the clinical definition of HCV "clearance" that is based on the results of two HCV RNA assays at least 6 months apart. It should also be noted that that we defined a positive HCV RNA result on the basis of an assay with a detection limit of 2500 copies/ml. In another analysis based on these test results, Tseng et al [24] found that the relative risks in UHS for previously reported predictors of chronic HCV infection (i.e., older age, African ancestry, presence of HBsAg, HIV infection) were very consistent with studies of 'HCV clearance' [25]. We are confident, therefore, that our study design is able to detect true differences in HCV outcome. We do not believe that our results are confounded by gender or HIV-1 status as we controlled for these variables in logistic regression models. The number of HIV-1-infected subjects in the study was too few for a meaningful evaluation of the independent effect of the MBL2 variants on HIV-1 serostatus.

Conclusion

In summary, our results suggest that HCV clearance is not among the infectious outcomes for which variants of MBL2 that cause MBL deficiency are deleterious. Our unexpected observation that MBL2 -289X was associated with the absence of HCV RNA in European Americans requires validation in other populations.

Declarations

Acknowledgements

The authors wish to thank: Ms. Myhanh Dotrang, Computer Sciences Corporation, for her assistance with database maintenance and data analysis; Mr. Wendell Miley for performing DNA extraction; and Amy Hutchinson for overseeing the genotyping. We also wish to honor the memory of Mr. Robert Welch, whose contributions as Director of Operations, NCI Core Genotyping Facility were essential to this paper.

Financial support: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and Division of Cancer Epidemiology and Genetics, with additional support from NIH grants R01-DA09532, R01-DA13245, and R01 DA16159. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Authors’ Affiliations

(1)
Division of Cancer Epidemiology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(2)
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services
(3)
SAIC-Frederick, Inc., Core Genotyping Facility, Advanced Technology Center, National Cancer Institute
(4)
Center for the Study of Hepatitis C, Weill Medical College of Cornell University
(5)
Urban Health Study, University of California

References

  1. Eisen DP, Minchinton RM: Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis. 2003, 37: 1496-505. 10.1086/379324.View ArticlePubMedGoogle Scholar
  2. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet. 1997, 349: 236-240. 10.1016/S0140-6736(96)08440-1.View ArticlePubMedGoogle Scholar
  3. Thio CL, Mosbruger T, Astemborski J, Greer S, Kirk GD, O'Brien SJ, Thomas DL: Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol. 2005, 79: 9192-9196. 10.1128/JVI.79.14.9192-9196.2005.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JA: Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet. 1996, 348: 1417-1419. 10.1016/S0140-6736(96)05409-8.View ArticlePubMedGoogle Scholar
  5. Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC, Ezekowitz RA: The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med. 1989, 170: 1175-1189. 10.1084/jem.170.4.1175.View ArticlePubMedGoogle Scholar
  6. Madsen HO, Garred P, Kurtzhals JA, Lamm LU, Ryder LP, Thiel S, Svejgaard A: A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics. 1994, 40: 37-44. 10.1007/BF00163962.View ArticlePubMedGoogle Scholar
  7. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA: Molecular basis of opsonic defect in immunodeficient children. Lancet. 1991, 337: 1569-1570. 10.1016/0140-6736(91)93263-9.View ArticlePubMedGoogle Scholar
  8. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995, 155: 3013-3020.PubMedGoogle Scholar
  9. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P: Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998, 161: 3169-75.PubMedGoogle Scholar
  10. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO: Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7: 85-94. 10.1038/sj.gene.6364283.View ArticlePubMedGoogle Scholar
  11. Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP: Mannan binding lectin and viral hepatitis. Immunol Lett. 2007, 108: 34-44. 10.1016/j.imlet.2006.10.006.View ArticlePubMedGoogle Scholar
  12. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR: Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001, 357: 1397-401. 10.1016/S0140-6736(00)04562-1.View ArticlePubMedGoogle Scholar
  13. NIH Consensus Statement on Management of Hepatitis C: NIH Consens State Sci Statements 2002. 2002, 19: 1-46. [http://consensus.nih.gov/2002/2002HepatitisC2002116main.htm]Google Scholar
  14. Seal KH, Kral AH, Lorvick J, Gee L, Tsui JI, Edlin BR: Among injection drug users, interest is high, but access low to HCV antiviral therapy. J Gen Intern Med. 2005, 20 (Suppl 1): 171-28th Annual Meeting of the Society of General Internal Medicine, New Orleans, Louisiana, 11-14 May 2005Google Scholar
  15. Bernig T, Breunis W, Brouwer N, Hutchinson A, Welch R, Roos D, Kuijpers T, Chanock S: An analysis of genetic variation across the MBL2 locus in Dutch Caucasians indicates that 3' haplotypes could modify circulating levels of mannose-binding lectin. Hum Genet. 2005, 118: 404-415. 10.1007/s00439-005-0053-5.View ArticlePubMedGoogle Scholar
  16. Bernig T, Taylor JG, Foster CB, Staats B, Yeager M, Chanock SJ: Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes Immun. 2004, 5: 461-76. 10.1038/sj.gene.6364116.View ArticlePubMedGoogle Scholar
  17. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, Gerhard DS, Chanock SJ: SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006, D617-21. 10.1093/nar/gkj151. 34 Database
  18. SNP500Cancer Database. [http://snp500cancer.nci.nih.gov]
  19. den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet. 2001, 109: 121-124. 10.1007/s004390100505.View ArticlePubMedGoogle Scholar
  20. Nomenclature for description of sequence variations in SNP500Cancer Database. [http://snp500cancer.nci.nih.gov/terms_snp_region.cfm]
  21. Brown EE, Fallin MD, Goedert JJ, Hutchinson A, Vitale F, Lauria C, Giuliani M, Marshall V, Mbisa G, Serraino D, Messina A, Durum S, Whitby D, Chanock SJ, Kaposi Sarcoma Genetics Working Group: Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis. 2006, 193: 1054-62. 10.1086/501470.View ArticlePubMedGoogle Scholar
  22. Soborg C, Madsen HO, Andersen AB, Lillebaek T, Kok-Jensen A, Garred P: Mannose-binding lectin polymorphisms in clinical tuberculosis. J Infect Dis. 2003, 188: 777-82. 10.1086/377183.View ArticlePubMedGoogle Scholar
  23. Alter MJ, Kuhnert WL, Finelli L: Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003, 52: 1-13. 15; quiz CE1-4PubMedGoogle Scholar
  24. Tseng FC, Edlin BR, Zhang M, Kral AH, Busch MP, Ortiz-Conde BA, Welzel TM, O'Brien TR: The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. Journal of Viral Hepatitis.
  25. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000, 284: 450-6. 10.1001/jama.284.4.450.View ArticlePubMedGoogle Scholar
  26. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/8/57/prepub

Copyright

© Brown et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement